India's DCGI Halts Avandia's TIDE Trial Aimed At Proving CV Safety; Steps Up Review of "Controversial Drugs" Sold In India
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - GlaxoSmithKline may be temporarily relieved after U.S. FDA's joint advisory committee recommended that GSK's controversial anti-diabetes drug Avandia (rosiglitazone) remain on the market; but dealing with the product seems to be getting tougher for the company in countries like India